About
Prostatype Genomics offers prostate cancer patients a decision support for the most optimal treatment option! We developed a test system called 'Prostatype® Test System'. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment. The Prostatype® Test System helps to choose the optimal treatment strategy for each patient. This secures quality of life for patients with a low risk tumor without jeopardizing safety for patients with aggressive tumors.
Technologies
OutlookMicrosoft Office 365YouTubeWistiaGoogle Tag ManagerWordPress.orgOpen AdStream (Appnexus)Mobile FriendlyVimeo
Keywords
prostate cancercancer prognosisoptimal treatmentunnecessary surgerymedical equipment manufacturingprognostic gene testoncology diagnosticshealthcare resourcesinternational studieshealth economicsrisk stratification in prostate cancerus market entryce-markedmedical researchgenomicsclinical parametershealthcare efficiencygene panel for prostate cancerprecision oncologykarolinska institutetmedical technologyeuropean market commercializationgene expression analysisbiomarker developmentmolecular diagnosticspersonalized medicineclinical validationprostate cancer diagnosisover-treatmentclinical decision support
Company Information
- Employees6
- Founded2007
- Annual Revenue$18000
Location
34 Gustav III:s boulevard, Stockholm County, Sweden, 169 73
